WHO Prioritizes MBP134, Remdesivir, and Obeldesivir for Bundibugyo Ebola Clinical Trials

With no licensed therapeutics or vaccines approved for Bundibugyo virus disease, WHO's advisory groups have handed drug developers and CDMOs a defined shortlist of candidates, and a clear mandate to move under clinical trial frameworks rather than compassionate use. The recommendations, issued in response to the active outbreak spanning the Democratic Republic of the Congo and Uganda, carry direct implications for manufacturers holding remdesivir, obeldesivir, and monoclonal antibody supply chains.

For treatment of confirmed BVD cases, WHO's R&D Blueprint technical advisory groups prioritized three candidates: monoclonal antibodies MBP134 and Maftivimab®, and the antiviral remdesivir. Combination therapy pairing a monoclonal antibody with remdesivir was also flagged for evaluation. For post-exposure prophylaxis, obeldesivir, an oral antiviral, was designated a priority candidate among contacts of confirmed and probable cases, contingent on functional contact-tracing infrastructure in affected areas.

On the vaccine side, the rVSV Bundibugyo candidate under development by IAVI carries the strongest profile but requires an estimated 7–9 months before it is trial-ready. Oxford University and Serum Institute of India's ChAdOx1 Bundibugyo could reach efficacy assessment within 2–3 months, though additional animal data remain outstanding. Ervebo, the only licensed Ebola vaccine, is not approved for BVD and WHO explicitly recommends against its use outside carefully designed research settings until cross-protection data are available.

For QA directors and regulatory affairs leads, the advisory groups' insistence on clinical trial deployment, rather than emergency unlicensed use, sets a clear GMP and data-integrity baseline. Sponsors and their contract manufacturers will need to demonstrate ICH Q10-aligned pharmaceutical quality systems and maintain audit-ready batch documentation from first-in-human dosing. The oral format of obeldesivir introduces solid-dosage scale-up considerations distinct from the parenteral monoclonal antibody and antiviral IV supply chains already in scope.

WHO is coordinating directly with the DRC and Ugandan governments to operationalize trial implementation, meaning site readiness, cold-chain logistics, and investigational product release timelines will converge under emergency conditions that historically compress standard validation cycles.

The pace at which ChAdOx1 Bundibugyo clears its outstanding animal data package will determine whether a two-dose regimen for high-risk unexposed populations, including healthcare workers, can be assessed within the current outbreak window.

Source: World Health Organization via WHO News (English), 28 May 2026.